In refractory systemic AOSD patients whose serum CRP and IL6 levels had normalized but hyperferritinemia and liver dysfunction had not improved and serum TNFα had not normalized under the conventional treatment, anti-TNF biologic might be more effective and safer treatment than at least anti-IL6 biologic as an adjunctive agent. This evidence concerns the gene IL6 and adult-onset Still disease.